The rising incidence of obesity and metabolic diseases such as diabetes mellitus and cardiovascular disease in adolescents and young adults is of grave concern. Recent studies favor a role of lifestyle factors over genetics in the perpetuation of inflammation, insulin resistance and oxidative stress, which are pathophysiologic processes common to the above diseases; furthermore, the importance of dietary factors in addition to calories and physical activity in these processes is being increasingly recognized. Advanced glycation end products (AGEs) belong to a category of dietary oxidants which have been implicated in the pathogenesis of inflammation, oxidative stress, insulin resistance, β-cell failure and endothelial dysfunction. This paper reviews the studies of AGEs with a focus on their role in cardiometabolic disease in children. A Medline search was performed using the key words ‘childhood obesity', ‘metabolic syndrome' and ‘advanced glycation end products'. Articles published in English between 1975 and 2015 and their references were reviewed. While most studies were performed in adults, a few studies also demonstrated a role of AGEs in obesity and associated cardiometabolic comorbidities in the younger population. Available evidence suggests an involvement of AGEs in the pathogenesis of adiposity and β-cell failure in children. Potential areas for further research to investigate underlying mechanisms are proposed.

Keywords:
Obesity, Children, Insulin resistance, Metabolic syndrome, Advanced glycation end products, Receptor of advanced glycation end products
1.
Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS: A potential decline in life expectancy in the United States in the 21st century. New Engl J Med 2005;352:1138-1145.
2.
Berenson GS, Wattigney WA, Tracy RE, Newman WP 3rd, Srinivasan SR, Webber LS, Dalferes ER Jr, Strong JP: Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6-30 years and studied at necropsy (the Bogalusa Heart Study). Am J Cardiol 1992;70:851-858.
3.
Yan SF, Ramsamy R, Schmidt AM: The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010;106:842-853.
4.
Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H: AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 2008;294:C145-C152.
5.
Kalea AZ, Schmidt AM, Hudson BI: RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009;116:621-637.
6.
Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-1031.
7.
Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-2835.
8.
Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Horig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM: The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:2916-2924.
9.
Yamagishi S, Matsui T: Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2:1184-1195.
10.
Chen YJ, Sheu ML, Tsai KS, Yang RS, Liu SH: Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLoS One 2013;8:e66611.
11.
Goldberg T, Cai W, Peppa M, Dardaine V, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-1291.
12.
He C, Sabol J, Mitsuhashi T, Vlassara H: Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999;48:1308-1315.
13.
Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997;94:6474-6479.
14.
Wu JC, Li XH, Peng YD, Wang JB, Tang JF, Wang YF: Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. J Endocrinol Invest 2011;34:e343-e348.
15.
Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y: Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007;76:236-244.
16.
Luciano Viviani G, Puddu A, Sacchi G, Garuti A, Storace D, Durante A, Monacelli F, Odetti P: Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro. Metabolism 2008;57:163-169.
17.
Lin N, Zhang H, Su Q: Advanced glycation end-products induce injury to pancreatic β cells through oxidative stress. Diabetes Metab 2012;38:250-257.
18.
Puddu A, Storace D, Durante A, Odetti P, Viviani GL: Glucagon-like peptide-1 counteracts the detrimental effects of advanced glycation end-products in the pancreatic β cell line HIT-T 15. Biochem Biophys Res Commun 2010;398:462-466.
19.
Hansen B, Svistounov D, Olsen R, Nagai R, Horiuchi S, Smedsrød B: Advanced glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia 2002;45:1379-1388.
20.
Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM: Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during trans-differentiation to myofibroblasts. Hepatology 2001;34:943-952.
21.
Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S: Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:1112-1119.
22.
Hyogo H, Yamagishi H: Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008;14:969-972.
23.
Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P, Giudicelli J, Beguinot F, Van Obberghen E: Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C α-mediated mechanism. J Biol Chem 2003;278:47376-47387.
24.
Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H: Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002;8:337-346.
25.
Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H: Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005;54:2314-2319.
26.
Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, Zeng F, Fisher EA, Vlassara H: Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002;51:2082-2089.
27.
Lin RY, Choudhury RP, Cai WJ, Lu M, Fallon JT, Fisher EA, et al: Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003;168:213-220.
28.
Lin RY, Reis ED, Dore AT, Lu M, Ghodsi N, Fallon JT, Fisher EA, Vlassara H: Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002;163:303-311.
29.
Zheng F, He CJ, Cai WJ, Hattori M, Steffes M, Vlassara H: Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002;18:224-237.
30.
Sebekova K, Fais V, Hofmann T, Schinzel R, Heidland A: Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. Am J Kidney Dis 2003;41:S48-S51.
31.
Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H: Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003;52:1441-1448.
32.
Cai WJ, Ramdas M, Zhu Li, Chen X, Striker GE, Vlassara H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin-1. Proc Natl Acad Sci USA 2012;109:15888-15893.
33.
Mericq V, Piccardo C, Cai W, Chen X, Zhu L, Striker GE, Vlassara H, Uribarri J: Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 2010;33:2232-2237.
34.
Klenovics KS, Boor P, Somoza V, Celec P, Fogliano V, Sebekova K: Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption. PLoS One 2013;8:e53056.
35.
Boor P, Celec P, Klenovicsová K, Vlková B, Szemes T, Minárik G, Turna J, Sebeková K: Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers. Clin Chim Acta 2010;411:1034-1040.
36.
Sebekova K, Somoza V, Jarcuskova M, Heidland A, Podracka L: Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009;4:112-118.
37.
Accacha S, Rosenfeld W, Jacobson A, Michel L, Schnurr FJ, Shelov S, Ten S, Boucher-Berry C, Carey DE, Speiser PW, Lowell B, Conroy R, Klein M, Fennoy I, Rapaport R, Rosenbaum M: Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children. Horm Res Paediatr 2013;80:318-327.
38.
Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J: Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009;94:4483-4491.
39.
Uribarri J, Cai W, Woodward M, Tripp E, Goldberg L, Pyzik R, Yee K, Tansman L, Chen X, Mani V, Fayad ZA, Vlassara H: Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? J Clin Endocrinol Metab 2015;100:1957-1966.
40.
Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, Hutton JC, Burger H, Schlosser M, Snieder H, Boehm BO, Leslie RD: Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes 2012;61:1192-1198.
41.
TODAY Study Group: Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757.
42.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
43.
de Giorgis T, D'Adamo E, Giannini C, Chiavaroli V, Scarinci A, Verrotti A, Chiarelli F, Mohn A: Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? Antioxid Redox Signal 2012;17:187-191.
44.
Chiavaroli V, D'Adamo E, Giannini C, de Giorgis T, De Marco S, Chiarelli F, Mohn A: Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care 2012;35:1361-1363.
45.
D'Adamo E, Giannini C, Chiavaroli V, de Giorgis T, Verrotti A, Chiarelli F, Mohn A: What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children? Antioxid Redox Signal 2011;14:1167-1172.
46.
Birlouez-Aragon I, Saavedra G, Tessier FJ, Galinier A, Ait-Ameur L, Lacoste F, Niamba CN, Alt N, Somoza V, Lecerf JM: A diet based on high heat treated foods promotes risk factors for DM and CVD. Am J Clin Nutr 2010;91:1220-1226.
47.
Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99:15596-15601.
48.
Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011;34:1610-1616.
49.
Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007;85:1236-1243.
50.
Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064-2071.
51.
D'Adamo E, Marcovecchio ML, Giannini C, de Giorgis T, Chiavaroli V, Chiarelli F, Mohn A: Improved oxidative stress and cardio-metabolic status in obese prepubertal children with liver steatosis treated with lifestyle combined with vitamin E. Free Radic Res 2013;47:146-153.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.